Table II.
Baseline characteristics of patients who received lenvatinib.
| Characteristics | All | High-level CD8+ TILs | Low-level CD8+ TILs | P-value |
|---|---|---|---|---|
| Number | 15 | 5 | 10 | |
| Age, years | 73 (62.0-80.0) | 74.5 (61.3-82.3) | 71.0 (64.5-74.5) | 0.759 |
| Sex, n (male/female) | 13/2 | 4/1 | 9/1 | 0.600 |
| Etiology | 0.069 | |||
| HBV | 4 | 2 | 2 | |
| HCV | 4 | 3 | 1 | |
| NBNC | 7 | 0 | 7 | |
| MVI positive, n | 3 | 2 | 1 | 0.182 |
| EHS positive, n | 2 | 1 | 1 | 0.600 |
| Intrahepatic max tumor size, cm | 3.0 (1.7-6.5) | 5.3 (1.8-8.3) | 3.0 (1.7-6.2) | 0.389 |
| Numbers of tumors >5 | 9 | 3 | 6 | 0.465 |
| Child-Pugh | 0.394 | |||
| Child-Pugh score A | 13 | 4 | 9 | 0.600 |
| Child-Pugh score B/C | 2 | 1 | 1 | |
| Alb, g/dl | 3.8 (3.1-4.4) | 4.2 (3.4-4.4) | 3.75 (3.48-4.4.1) | 0.723 |
| T.Bil, g/dl | 0.9 (0.7-1.1) | 1.0 (0.9-1.35) | 0.75 (0.68-1.1) | 0.275 |
| ALBI score | −2.56 (−3.03-2.18) | −2.75 (−2.96-1.99) | −2.44 (−3.05-2.13 | 0.977 |
| BCLC stage | 0.061 | |||
| A | 1 | 0 | 1 | |
| B | 12 | 3 | 9 | |
| C | 2 | 2 | 0 | |
| Tumor marker | ||||
| AFP, ng/ml | 6.7 (3.3-23.7) | 2,317 (6.6-6080.7) | 6.2 (2.8-7.1) | 0.657 |
| PIVKA-II, mAU/ml | 138 (42–1135) | 77 (38.5-8650.5) | 266 (38.8-2571.3) | 0.575 |
Data are expressed as median (interquartile range). TILs, tumor-infiltrating lymphocytes; HBV, hepatitis B virus; HCV, hepatitis C virus; MVI, microvascular invasion; EHS, extrahepatic spread; Alb, albumin; T.Bil, total bilirubin; ALBI score, albumin-bilirubin score; BCLC stage, Barcelona Clinic liver cancer stage; AFP, α-fetoprotein; PIVKA-II, vitamin K absence or antagonist-II.